Invesco Ltd. Has $248.47 Million Stock Holdings in argenx SE (NASDAQ:ARGX)

Invesco Ltd. cut its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 6.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 404,016 shares of the company's stock after selling 29,500 shares during the quarter. Invesco Ltd. owned approximately 0.66% of argenx worth $248,470,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Whipplewood Advisors LLC bought a new stake in argenx during the fourth quarter worth about $37,000. Global Retirement Partners LLC boosted its position in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after acquiring an additional 48 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after acquiring an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in argenx by 78.6% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after acquiring an additional 33 shares during the last quarter. Finally, Huntington National Bank grew its stake in argenx by 1,133.3% in the 4th quarter. Huntington National Bank now owns 74 shares of the company's stock worth $46,000 after acquiring an additional 68 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Down 2.0 %

NASDAQ ARGX traded down $11.94 during midday trading on Wednesday, hitting $593.44. The company had a trading volume of 90,655 shares, compared to its average volume of 307,999. The firm has a fifty day simple moving average of $605.51 and a two-hundred day simple moving average of $604.95. The stock has a market cap of $36.06 billion, a price-to-earnings ratio of -674.37 and a beta of 0.60. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21.

Remove Ads

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million. As a group, equities analysts predict that argenx SE will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of argenx from $650.00 to $680.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Wedbush reiterated an "outperform" rating and set a $715.00 price objective on shares of argenx in a research note on Friday, April 11th. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 price target on shares of argenx in a report on Tuesday, April 8th. Finally, Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $690.33.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.